SCHEMBL13767281

SCHEMBL13767281

CC(C)NC(=O)N1CCC(CCn2ncc(C(=O)NC3C4CC5CC(C4)CC3C5)c2OC(C)C)CC1

nearest known ligand 0.39

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 11/20 0.39
LMNA P02545 2/20 0.37
HTT P42858 1/20 0.37
CNR2 P34972 4/20 0.37
HPGD P15428 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
EPHX2 P34913 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13767299 0.89 HSD11B1 (0.39) HSD11B1LMNAHTTCNR2
SCHEMBL13767277 0.86 HSD11B1 (0.40) HSD11B1LMNAHTTCNR2HPGD
SCHEMBL13767278 0.85 HSD11B1 (0.39) HSD11B1LMNAHTTCNR2HPGD
SCHEMBL13767267 0.85 HSD11B1 (0.41) HSD11B1LMNAHTTCNR2HPGD
SCHEMBL13767263 0.81 HSD11B1 (0.39) HSD11B1LMNAHTTCNR2
SCHEMBL13767265 0.80 HSD11B1 (0.41) HSD11B1LMNAHTTCNR2HPGD
SCHEMBL13767286 0.79 HSD11B1 (0.39) HSD11B1LMNAHTTCNR2
SCHEMBL13767259 0.78 KDM4E (0.41) HSD11B1LMNAHTTHPGD
SCHEMBL13767295 0.78 HSD11B1 (0.53) HSD11B1
SCHEMBL13767102 0.77 HSD11B1 (0.42) HSD11B1LMNAHTTCNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1953145-B1 HETEROCYCLIC COMPOUND HAVING INHIBITORY ACTIVITY ON 11-B-HYDROXYSTEROID DEHYDROGENASE TYPE I SHIONOGI & CO (JP) 2015-11-04 EP disclosed
US-8324265-B2 Heterocyclic compounds having type I 11β hydroxysteroid dehydrogenase inhibitory activity SHIONOGI & CO., LTD. (JP) 2012-12-04 US disclosed
US-8324265-B2 Heterocyclic compounds having type I 11β hydroxysteroid dehydrogenase inhibitory activity SHIONOGI & CO., LTD. (JP) 2012-12-04 US disclosed
US-20090170832-A1 HETEROCYCLIC COMPOUNDS HAVING TYPE I 11beta HYDROXYSTEROID DEHYDROGENASE INHIBITORY ACTIVITY SHIONOGI & CO., LTD. (JP) 2009-07-02 US disclosed
US-20090170832-A1 HETEROCYCLIC COMPOUNDS HAVING TYPE I 11beta HYDROXYSTEROID DEHYDROGENASE INHIBITORY ACTIVITY SHIONOGI & CO., LTD. (JP) 2009-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170832-A1 HETEROCYCLIC COMPOUNDS HAVING TYPE I 11beta HYDROXYSTEROID DEHYDROGENASE INHIBITORY ACTIVITY HSD17B1, HSD11B1, HSD3B1 HSD11B1 2/4885LMNA 2271/4885HTT 3719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.